1,525
Views
31
CrossRef citations to date
0
Altmetric
Author's View

CD73-adenosine reduces immune responses and survival in ovarian cancer patients

, , &
Article: e1127496 | Received 23 Nov 2015, Accepted 27 Nov 2015, Published online: 31 May 2016

Figures & data

Figure 1. High CD73 expression in high-grade serous ovarian cancers promotes tumor cell survival and immune escape. CD73 expression on both tumor cells and cancer-associated fibroblasts (CAFs) can be induced in the ovarian tumor microenvironment (TME). When CD73 is highly expressed, adenosine accumulates in the TME and mediates immunosuppressive effects on antitumor immune cells, such as CD8+ T cells. Extracellular adenosine also promotes ovarian cancer cell survival in an autocrine or paracrine manner. Hence, HGSC patients with high levels of CD73 in the TME have a worse prognosis and show impaired CD8+ T cell-mediated antitumor immunity. Conversely, patients with low levels of CD73 have a better prognosis associated with functional antitumor CD8+ T cells. Ado: Adenosine. AMP: Adenosine monophosphate.

Figure 1. High CD73 expression in high-grade serous ovarian cancers promotes tumor cell survival and immune escape. CD73 expression on both tumor cells and cancer-associated fibroblasts (CAFs) can be induced in the ovarian tumor microenvironment (TME). When CD73 is highly expressed, adenosine accumulates in the TME and mediates immunosuppressive effects on antitumor immune cells, such as CD8+ T cells. Extracellular adenosine also promotes ovarian cancer cell survival in an autocrine or paracrine manner. Hence, HGSC patients with high levels of CD73 in the TME have a worse prognosis and show impaired CD8+ T cell-mediated antitumor immunity. Conversely, patients with low levels of CD73 have a better prognosis associated with functional antitumor CD8+ T cells. Ado: Adenosine. AMP: Adenosine monophosphate.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.